

**For More Information Contact:**

Michael Schmainda  
[mike@imagingbiometrics.com](mailto:mike@imagingbiometrics.com)  
Imaging Biometrics, LLC

**ACRIN ENTERS AGREEMENT WITH IMAGING BIOMETRICS FOR ADVANCED IMAGING TRIAL**

***IB'S MR Perfusion Software Will Evaluate Mechanisms of AntiAngiogenic Drugs***

**Milwaukee, WI, June 11<sup>th</sup>, 2008** – Imaging Biometrics, LLC (IB), a provider of advanced visualization and analytical software solutions, has an agreement with the American College of Radiology Imaging Network (ACRIN) to evaluate magnetic resonance imaging (MRI) datasets using its proprietary dynamic susceptibility contrast (DSC) MR perfusion software, IB Neuro™. The ACRIN trial (#6677) is a global multi-center phase II trial using advanced imaging to track the effectiveness of biological treatments for brain tumors. IB Neuro™ uses DSC algorithms to provide information about blood volume and blood flow in the brain. These critical perfusion parameters are valuable for detecting new tumor growth or tumor recurrence, and should assist in tailoring personalized treatment plans for patients. MR perfusion imaging may also play an important role in the development of improved treatment therapies, which is another objective of this study.

ACRIN Principal Investigator Gregory Sorensen, M.D., Harvard Professor and Co-Director of the A.A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital, says, "This study marries advanced imaging techniques with one of the most important topics in oncology today: antiangiogenic drugs. We hope that by doing this study we'll understand better how antiangiogenic drugs work, how imaging can shed light on making decisions about therapeutic choices, and how to better develop improved treatments for cancer."

**IB Neuro™**

Recently cleared by the FDA, IB Neuro™ incorporates proprietary algorithms to correct for contrast agent leakage to more consistently distinguish between normal and abnormal tissue. This rich information should enable better decisions in tailoring individual treatment plans for patients with brain tumors and other brain disorders.

"We are delighted that ACRIN has contracted with us to assist them in this important clinical initiative", said Michael Schmainda, IB's President and CEO. "Participating in this trial will help advance healthcare and leveraging the computational power of IB Neuro™ is a very cost-effective way to provide the results".

**ACRIN 6677**

The study, *ACRIN 6677/RTOG-0625, A Randomized Phase II Trial of Bevacizumab with Irinotecan or Bevacizumab with Temozolomide in Recurrent Glioblastoma*, will determine whether the drug bevacizumab, in combination with one of two other drugs, is effective in treating glioblastoma. A key part of this study will be exploring whether three different advanced MRI techniques can act as biomarkers by providing valuable information about patients' response to treatment.

**About Imaging Biometrics™ LLC**

Imaging Biometrics develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine clinical workflows. For more information about Imaging Biometrics, visit the company's website at [www.imagingbiometrics.com](http://www.imagingbiometrics.com)